MX2016006486A - Anticuerpos. - Google Patents
Anticuerpos.Info
- Publication number
- MX2016006486A MX2016006486A MX2016006486A MX2016006486A MX2016006486A MX 2016006486 A MX2016006486 A MX 2016006486A MX 2016006486 A MX2016006486 A MX 2016006486A MX 2016006486 A MX2016006486 A MX 2016006486A MX 2016006486 A MX2016006486 A MX 2016006486A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- antibodies
- matriptase
- treatment
- lymphoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La invención proporciona anticuerpos los cuales se unen al dominio extracelular del receptor transmembrana de tirosina - proteína quinasa Matriptasa. También se proveen moléculas de ácido nucleico que codifican los anticuerpos, vectores de expresión, células huéspedes y métodos para expresar los anticuerpos. Los anticuerpos pueden utilizarse para el tratamiento del cáncer, incluyendo cáncer gástrico, cáncer colorrectal, cáncer de próstata, cáncer mamario, cáncer de ovario, cáncer pulmonar, preferentemente SCLC, cancer de esófago, cáncer de cabeza y cuello, cáncer pancreático, linfoma preferentemente linfoma no de Hodgkin y cáncer de piel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361908371P | 2013-11-25 | 2013-11-25 | |
PCT/GB2014/053470 WO2015075477A1 (en) | 2013-11-25 | 2014-11-25 | Antibodies anti matriptase for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006486A true MX2016006486A (es) | 2016-08-05 |
Family
ID=52000873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006486A MX2016006486A (es) | 2013-11-25 | 2014-11-25 | Anticuerpos. |
Country Status (14)
Country | Link |
---|---|
US (1) | US9932411B2 (es) |
EP (1) | EP3074423A1 (es) |
JP (1) | JP2016538852A (es) |
KR (1) | KR20160079818A (es) |
CN (1) | CN105849127A (es) |
AR (1) | AR098523A1 (es) |
AU (1) | AU2014351565A1 (es) |
BR (1) | BR112016011435A2 (es) |
CA (1) | CA2929402A1 (es) |
EA (1) | EA201690806A1 (es) |
IL (1) | IL245551A0 (es) |
MX (1) | MX2016006486A (es) |
TW (1) | TW201605905A (es) |
WO (1) | WO2015075477A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
EP3074423A1 (en) | 2013-11-25 | 2016-10-05 | Oxford BioTherapeutics Ltd | Antibodies anti matriptase for the treatment of cancer |
AU2017235571B2 (en) * | 2016-03-18 | 2024-05-16 | Georgetown University | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7022821B1 (en) | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
US5972616A (en) | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
JP4778617B2 (ja) | 1999-03-12 | 2011-09-21 | ジョージタウン ユニバーシティ | マトリプターゼ、セリンプロテアーゼおよびその応用 |
US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
EP1226150A4 (en) | 1999-10-20 | 2005-05-25 | Univ Arkansas | TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA |
US6447978B1 (en) | 1999-12-03 | 2002-09-10 | Kodak Polychrome Graphics Llc | Imaging member containing heat switchable polymer and method of use |
DE60143880D1 (de) | 2000-02-03 | 2011-03-03 | Dendreon Corp | Nukleinsäuren, welche für tramsmembran serin proteasen kodieren, die kodierten proteine und darauf basierende methoden |
US6903201B2 (en) | 2001-01-05 | 2005-06-07 | Curagen Corporation | Proteins and nucleic acids encoding same |
WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
KR20040011480A (ko) | 2001-03-22 | 2004-02-05 | 덴드레온 샌 디에고 엘엘씨 | 세린 프로테아제 cvsp14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법 |
EP1379637A4 (en) | 2001-03-27 | 2005-04-06 | Dendreon Corp | TRANSMEMBRANE SERINE PROTEASE 9 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED, AND METHODS FORMING THEREOF |
EP1539942A4 (en) | 2001-05-14 | 2005-10-19 | Dendreon Corp | A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF |
US20030170245A1 (en) * | 2002-03-05 | 2003-09-11 | Dickson Robert B. | Activation of matriptase and diagnostic and therapeutic methods based thereon |
US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
ATE504602T1 (de) | 2004-12-20 | 2011-04-15 | Amgen Fremont Inc | Für humane matriptase spezifische bindungsproteine |
EP1851543A2 (en) | 2005-02-24 | 2007-11-07 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
WO2007047796A2 (en) | 2005-10-17 | 2007-04-26 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
ES2550754T3 (es) | 2007-08-07 | 2015-11-12 | Oxford Biotherapeutics Ltd. | Proteína matriptasa y usos de la misma |
SI2285408T1 (sl) * | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
US8205227B1 (en) | 2010-02-06 | 2012-06-19 | Frontier Communications Corporation | Management and delivery of audiovisual content items that correspond to scheduled programs |
KR20130091132A (ko) * | 2012-02-07 | 2013-08-16 | 한국생명공학연구원 | 메트립타아제-특이적인 인간 항체 및 그의 용도 |
EP3074423A1 (en) | 2013-11-25 | 2016-10-05 | Oxford BioTherapeutics Ltd | Antibodies anti matriptase for the treatment of cancer |
-
2014
- 2014-11-25 EP EP14805644.3A patent/EP3074423A1/en not_active Withdrawn
- 2014-11-25 CA CA2929402A patent/CA2929402A1/en not_active Abandoned
- 2014-11-25 TW TW103140877A patent/TW201605905A/zh unknown
- 2014-11-25 US US15/037,929 patent/US9932411B2/en not_active Expired - Fee Related
- 2014-11-25 WO PCT/GB2014/053470 patent/WO2015075477A1/en active Application Filing
- 2014-11-25 BR BR112016011435A patent/BR112016011435A2/pt not_active Application Discontinuation
- 2014-11-25 AR ARP140104405A patent/AR098523A1/es unknown
- 2014-11-25 JP JP2016532094A patent/JP2016538852A/ja active Pending
- 2014-11-25 KR KR1020167013234A patent/KR20160079818A/ko not_active Application Discontinuation
- 2014-11-25 EA EA201690806A patent/EA201690806A1/ru unknown
- 2014-11-25 MX MX2016006486A patent/MX2016006486A/es unknown
- 2014-11-25 AU AU2014351565A patent/AU2014351565A1/en not_active Abandoned
- 2014-11-25 CN CN201480070410.1A patent/CN105849127A/zh active Pending
-
2016
- 2016-05-09 IL IL245551A patent/IL245551A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2929402A1 (en) | 2015-05-28 |
JP2016538852A (ja) | 2016-12-15 |
US20160289338A1 (en) | 2016-10-06 |
AR098523A1 (es) | 2016-06-01 |
AU2014351565A1 (en) | 2016-06-09 |
TW201605905A (zh) | 2016-02-16 |
EA201690806A1 (ru) | 2016-09-30 |
EP3074423A1 (en) | 2016-10-05 |
US9932411B2 (en) | 2018-04-03 |
BR112016011435A2 (pt) | 2017-09-26 |
IL245551A0 (en) | 2016-06-30 |
KR20160079818A (ko) | 2016-07-06 |
WO2015075477A1 (en) | 2015-05-28 |
CN105849127A (zh) | 2016-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123355T1 (el) | Αντισωματα εναντι cd73 και χρησεις εξ αυτων | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
MX2019012846A (es) | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. | |
NZ720353A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
UA115034C2 (uk) | Імунокон'югат для застосування в лікуванні раку або запального порушення | |
MX2019006411A (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos. | |
PH12015501134B1 (en) | Egfr and c-met-fibronectin type iii domain binding molecules | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
PH12014502179B1 (en) | Ang2-binding molecules | |
PH12016500580B1 (en) | Conjugated antibodies against ly75 for the treatment of cancer | |
NZ722076A (en) | Chimeric antigen receptor containing a toll-like receptor intracellular domain | |
MX2013011354A (es) | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. | |
MX2016006486A (es) | Anticuerpos. |